Agonism of DR3 for Enhanced Treg Cell Function in IBD
DR3 的激动作用可增强 IBD 中的 Treg 细胞功能
基本信息
- 批准号:10093029
- 负责人:
- 金额:$ 4.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-02-01 至 2023-01-31
- 项目状态:已结题
- 来源:
- 关键词:ATAC-seqAdaptive Immune SystemAffectAgonistAmericanAnti-Inflammatory AgentsAntibodiesApoptoticAutoantigensBiologicalBiological Response Modifier TherapyBiological Response ModifiersBlocking AntibodiesCD4 Positive T LymphocytesCell SurvivalCell TherapyCell physiologyCellsChronicColitisColonCompetenceDataDevelopmentDiseaseDisease ManagementEffector CellEquilibriumEtiologyExposure toFOXP3 geneFlareFoundationsGastroenterologyGenetic TranscriptionGoalsHistonesHomeostasisHumanImmuneImmune responseImmune systemImmunityIn VitroInflammationInflammatoryInflammatory Bowel DiseasesInflammatory ResponseInterleukin-10Intestinal DiseasesIntestinesLifeMaintenanceMediatingMethodsMusMutationNaturePathogenesisPathway interactionsPatientsPhenotypePlayPopulationPrevalencePreventionProcessProductionProtocols documentationRegulatory T-LymphocyteRelapseReporterResearchResolutionRoleSignal TransductionStimulusT cell responseT-LymphocyteTNFRSF1A geneTRAMP proteinTherapeuticTissuesTransgenic MiceTumor Necrosis Factor ReceptorWorkarmbasecareercommensal microbescytokinedensityimmunoregulationin vivoinflammatory disease of the intestineintestinal homeostasismembermouse modelnovelprogramsreceptorstemsystemic autoimmunitytherapeutic developmenttranscriptome sequencing
项目摘要
PROJECT SUMMARY
The immune-mediated, chronic inflammation in inflammatory bowel disease (IBD) leads to flares that often
require patients to be treated with life-long biologic therapy. Recently, efforts in IBD disease management have
focused on the potential of regulatory T (Treg) cell-based therapy as an alternative to traditional treatments. Treg
cells limit inflammatory responses to both foreign and self-antigens and can become further differentiated into
potently suppressive effector Tregs (eTregs) upon exposure to immune stimuli. eTregs, especially those that
produce the immunosuppressive cytokine interleukin 10 (IL-10), play a critical, mitigating role in both human and
murine colitis. However, the signals that induce and functionally enhance this subset are not well understood,
largely because they are limited in number and there have been no suitable protocols to differentiate them in
vitro. Here, we have identified a signal that enhances the expansion and maintenance of IL-10+ eTregs in vivo
and in vitro. Death receptor 3 (DR3 or TNFRSF25) is a tumor necrosis factor receptor superfamily (TNFRSF)
member that is constitutively expressed by activated T cells and has been found to both enhance and suppress
the immune response. We have found that treatment with an agonist antibody to DR3 (aDR3) significantly
enhances the proliferation and cell survival specifically of IL-10+ eTregs. Additionally, treatment greatly expands
total Treg cells in many tissues, but the effect is most profound in the intestine. To our knowledge, the observation
that aDR3 expands IL-10 producing eTregs has not yet been described. This proposal will determine the
mechanisms by which DR3 signaling induces increased intestinal Tregs (Aim 1), as well as the potential of aDR3
as a therapeutic in the treatment of colitis (Aim 2). We will utilize a novel transgenic mouse model that lacks DR3
specifically in Tregs to understand the role that DR3 signaling plays in intestinal Treg function in both the steady
state and in the inflamed colon. By using our IL-10 and Foxp3 dual reporter mouse, we will be able to stratify
Treg populations by IL-10 competency, which will allow us to characterize the mechanisms by which DR3
differentially enhances Treg cell subsets. Our central hypothesis is that the effect of DR3 signaling is two-fold in
that it: (1) primes Treg cells for an effector phenotype; and (2) enacts a specific program that impacts eTreg
survival, stability, and function. Understanding how this pathway augments Treg cell function will have broad-
reaching implications not only in the field of IBD, but also in the management of a number of immune-mediated
diseases.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Emma C Dean其他文献
Emma C Dean的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Emma C Dean', 18)}}的其他基金
Agonism of DR3 for Enhanced Treg Cell Function in IBD
DR3 的激动作用可增强 IBD 中的 Treg 细胞功能
- 批准号:
10319918 - 财政年份:2019
- 资助金额:
$ 4.71万 - 项目类别:
Agonism of DR3 for Enhanced Treg Cell Function in IBD
DR3 的激动作用可增强 IBD 中的 Treg 细胞功能
- 批准号:
9756688 - 财政年份:2019
- 资助金额:
$ 4.71万 - 项目类别:
相似海外基金
Single-cell analysis of adaptive immune system cells in IBD patients
IBD 患者适应性免疫系统细胞的单细胞分析
- 批准号:
22KJ2212 - 财政年份:2023
- 资助金额:
$ 4.71万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
- 批准号:
10740465 - 财政年份:2023
- 资助金额:
$ 4.71万 - 项目类别:
Elucidation of the adaptive immune system in teleost fish
阐明硬骨鱼的适应性免疫系统
- 批准号:
22K05824 - 财政年份:2022
- 资助金额:
$ 4.71万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Interaction of Galectin-9 and Pregnancy-Specific Glycoprotein 1 in the Regulation of Cells of the Innate and Adaptive Immune System
Galectin-9 和妊娠特异性糖蛋白 1 在先天性和适应性免疫系统细胞调节中的相互作用
- 批准号:
10434937 - 财政年份:2021
- 资助金额:
$ 4.71万 - 项目类别:
Peripheral Adaptive Immune System Changes Associated with Alzhiemer's Disease
与阿尔茨海默病相关的外周适应性免疫系统变化
- 批准号:
10194864 - 财政年份:2021
- 资助金额:
$ 4.71万 - 项目类别:
Interaction of Galectin-9 and Pregnancy-Specific Glycoprotein 1 in the Regulation of Cells of the Innate and Adaptive Immune System
Galectin-9 和妊娠特异性糖蛋白 1 在先天性和适应性免疫系统细胞调节中的相互作用
- 批准号:
10302501 - 财政年份:2021
- 资助金额:
$ 4.71万 - 项目类别:
Learning a molecular shape space for the adaptive immune system
学习适应性免疫系统的分子形状空间
- 批准号:
10275426 - 财政年份:2021
- 资助金额:
$ 4.71万 - 项目类别:
CAREER: Emergence of Functional Organization in the Adaptive Immune System
职业:适应性免疫系统中功能组织的出现
- 批准号:
2045054 - 财政年份:2021
- 资助金额:
$ 4.71万 - 项目类别:
Continuing Grant
Learning a molecular shape space for the adaptive immune system
学习适应性免疫系统的分子形状空间
- 批准号:
10669709 - 财政年份:2021
- 资助金额:
$ 4.71万 - 项目类别:
Learning a molecular shape space for the adaptive immune system
学习适应性免疫系统的分子形状空间
- 批准号:
10467050 - 财政年份:2021
- 资助金额:
$ 4.71万 - 项目类别: